Related Experiment Video
Updated: Jul 13, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells
Thomas Efferth1, Marco Giaisi, Annette Merling
1Pharmaceutical Biology of Natural Products, German Cancer Research Center, Heidelberg, Germany.
Background:
A major obstacle for successful cancer treatment often is the development of drug resistance in cancer cells during chemotherapy. Therefore, there is an urgent need for novel drugs with improved efficacy against tumor cells and with less toxicity on normal cells. Artesunate (ART), a powerful anti-malarial herbal compound, has been shown to inhibit growth of various tumor cell lines in vitro and of xenografted Kaposi's sarcoma in mice in vivo. However, the molecular mechanisms by which ART exerts its cytotoxicity have not been elucidated. The ART-class of anti-malarial compounds is attractive due to their activity against multidrug-resistant Plasmodium falciparum and Plasmodium vivax strains. Another salient feature of these compounds is the lack of severe side effects in malaria patients.
Methodology And Principal Findings:
In this study, we used T-cell leukemias as a model system to study the molecular mechanisms of ART-induced apoptosis. The most typical anticancer drugs are DNA intercalators such as Doxorubicin. To investigate drug sensitivity and resistance, we chose a Doxorubicin-resistant leukemia cell line and investigated the killing effect of ART on these cells. We show that ART induces apoptosis in leukemic T cells mainly through the mitochondrial pathway via generation of reactive oxygen species (ROS), a mechanism different from Doxorubicin. This is confirmed by the fact that the antioxidant N-Acetyle-Cysteine (NAC) could completely block ROS generation and, consequently, inhibited ART-induced apoptosis. Therefore, ART can overcome the Doxorubicin-resistance and induce the Doxorubicin-resistant leukemia cells to undergo apoptosis. We also show that ART can synergize with Doxorubicin to enhance apoptotic cell death in leukemic T cells. This synergistic effect can be largely explained by the fact that ART and Doxorubicin use different killing mechanisms.
Conclusions:
Our studies raise the possibility to develop ART in combination with other established anticancer drugs which induce apoptosis through the pathways or mechanisms different from ART.
Insights
Artesunate (ART) induces apoptosis in drug-resistant leukemia cells via mitochondrial reactive oxygen species (ROS) generation, overcoming chemotherapy resistance. ART also synergizes with Doxorubicin, offering new combination therapy potential.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Chemotherapy resistance is a major challenge in cancer treatment, necessitating novel therapeutic agents.
- Artesunate (ART), an anti-malarial drug, shows promise against various cancer cell lines and lacks severe side effects.
- The precise molecular mechanisms of ART's anti-cancer activity remain largely unelucidated.
Purpose of the Study:
- To investigate the molecular mechanisms underlying Artesunate (ART)-induced apoptosis in T-cell leukemias.
- To determine if ART can overcome Doxorubicin resistance in leukemia cells.
- To explore the potential synergistic effects of ART in combination with Doxorubicin.
Main Methods:
- Utilized a Doxorubicin-resistant T-cell leukemia model system.
- Investigated ART's cytotoxic effects and the role of mitochondrial pathways and reactive oxygen species (ROS).
- Assessed the impact of the antioxidant N-Acetyl-Cysteine (NAC) on ART-induced apoptosis.
Main Results:
- ART induces apoptosis in leukemic T cells primarily through the mitochondrial pathway, involving ROS generation.
- ART effectively overcomes Doxorubicin resistance, inducing apoptosis in resistant leukemia cells.
- ART demonstrates a synergistic effect with Doxorubicin, enhancing cancer cell death through distinct mechanisms.
Conclusions:
- Artesunate (ART) offers a novel mechanism for inducing apoptosis, distinct from traditional chemotherapy agents like Doxorubicin.
- ART has the potential to overcome drug resistance in leukemia and other cancers.
- ART may be a valuable component in combination cancer therapies, targeting resistant tumors.
Related Concept Videos
Antiprotozoal Agents
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
